Inalgex (Etofenamate)

Etofenamate blocks cyclooxygenase enzymes (COX‑1 and COX‑2) in the skin and underlying tissues, which lowers prostaglandin production. Reduced prostaglandins diminish inflammation, swelling, and pain signals, delivering a targeted anti‑inflammatory and analgesic effect at the site of application.

The dosage of Inalgex is determined by the prescribing healthcare professional based on the specific condition, severity, and patient factors. The prescriber will specify the amount to apply, frequency, and duration of treatment.

Safety of topical etofenamate in pregnancy or lactation has not been fully established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks with their healthcare provider before using Inalgex.

To request Inalgex, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Inalgex delivers etofenamate, a potent NSAID with strong COX inhibition, similar to other topical agents like diclofenac or ketoprofen. Compared with some alternatives, etofenamate may offer a higher anti‑inflammatory potency, but individual response and tolerability can vary, so clinicians choose based on patient needs and safety profile.

Inalgex should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture, direct sunlight, and extreme heat to maintain product stability.

Inalgex is applied topically to the affected skin area. The prescribed amount is spread thinly and gently massaged into the skin, usually 2–4 times daily, or as directed by the healthcare professional. Hands should be washed before and after application.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and systemic NSAID effects like gastrointestinal bleeding, renal impairment, or liver dysfunction. Patients should seek immediate medical attention if they notice signs of a severe reaction.

Inalgex should be avoided in individuals with known hypersensitivity to etofenamate or any component of the formulation, those with broken or infected skin at the intended site, and patients taking systemic anticoagulants or other NSAIDs without medical supervision.